AbbVie Submits Upadacitinib for Vitiligo Treatment Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2026
0mins
Should l Buy ABBV?
Source: Newsfilter
AbbVie Inc. is experiencing a pre-market decline of 7.19%, hitting a 20-day low amid mixed market conditions, with the Nasdaq-100 down 0.24% and the S&P 500 up 0.10%.
The decline comes despite AbbVie's recent submission of upadacitinib for FDA and EMA approval for treating non-segmental vitiligo, following successful clinical study results that demonstrated significant improvements in skin re-pigmentation. This potential breakthrough could address a critical treatment gap for patients suffering from this chronic autoimmune disease, indicating strong future growth prospects for the company.
The market's mixed performance may have contributed to the stock's downward movement, reflecting sector rotation as investors reassess their positions in response to broader market trends.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 202.710
Low
223.00
Averages
252.00
High
289.00
Current: 202.710
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dividend Stocks Comparison: Johnson & Johnson vs. AbbVie
- Diversification Advantage: Johnson & Johnson's diversified operations in pharmaceuticals and medical devices allow it to maintain stability in a competitive market, with revenue growth despite losing Stelara's patent, and it is projected to reach $100 billion in revenue by 2026, becoming only the second biopharma to achieve this milestone in history.
- Core Growth Drivers for AbbVie: AbbVie's leadership in immunology led to $15 billion in revenue in Q1, a 12.4% year-over-year increase, with Skyrizi and Rinvoq contributing $6.6 billion, showcasing strong market performance, though it faces competitive risks.
- Dividend Growth History: Johnson & Johnson has raised its dividends for 64 consecutive years compared to AbbVie's 54 years, indicating stronger financial stability and long-term investment appeal, particularly in the current market environment, with its AAA credit rating further enhancing its attractiveness as a low-risk investment.
- Market Risks and Opportunities: While Johnson & Johnson faces litigation risks related to its talc products, its diversified portfolio enables it to navigate challenges like drug pricing negotiations, whereas AbbVie shows potential in new product launches, especially with its weight-loss treatment performing well in clinical trials.
See More
Analysis of IVV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The IVV ETF's 52-week low is $558.69 per share, with a high of $734.02, and the latest trade at $733.89 indicates stability near its peak, potentially attracting investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- Unit Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding highlights notable inflows (new units created) or outflows (old units destroyed), directly affecting the ETF's underlying holdings and its market performance.
See More
High Dividend Stocks Investors Should Focus On
- AbbVie Dividend Stability: AbbVie declared a quarterly cash dividend of $1.73 per share, and despite losing patent protection for Humira, the company has successfully achieved growth through strategic acquisitions and R&D investments, indicating a strong potential for continued dividends in the future.
- Significant Dividend Growth: Since its spin-off in 2013, AbbVie has increased its dividend by over 332%, with a 33% growth in the past five years, and a current dividend yield of 3.27%, which, although below historical averages, still reflects the company's robust profitability.
- Realty Income's Monthly Dividends: Realty Income, known as
See More
AbbVie and Realty Income's Stable Dividend Prospects
- AbbVie Dividend Growth: AbbVie's board declared a quarterly cash dividend of $1.73 per share, payable on May 15, 2026, demonstrating the company's ability to increase dividends for 54 consecutive years, even amidst patent expiration challenges, while maintaining robust business growth.
- Dividend Yield Performance: AbbVie's forward dividend yield stands above 3.3%, although below its historical average, yet its solid stock price appreciation and 33% dividend growth over the past five years indicate effective inflation management.
- Realty Income Stability: Realty Income has paid dividends for 670 consecutive quarters since going public in 1994, with a forward dividend yield exceeding 5%, showcasing its ability to generate steady cash flow and maintain a high occupancy rate of 98.9% even during economic fluctuations.
- Market Growth Potential: Realty Income's total addressable market is estimated at $13 trillion, with $8.5 trillion in Europe, indicating significant growth potential in a highly fragmented market, which suggests the company can continue to provide substantial monthly dividends to investors.
See More
Apple, Amazon, and TSMC Deliver Earnings Triple Plays
- Earnings Highlights: Apple, Amazon, and TSMC have all achieved a 'triple play' this quarter, delivering growth in earnings, revenue, and guidance, which underscores strong market demand and business resilience, further solidifying their leadership positions in their respective industries.
- Market Reaction: Investors reacted positively to the earnings reports from these three companies, driving stock prices higher, which reflects a renewed confidence in tech stocks and may attract more capital inflows into the technology sector.
- Industry Impact: The robust performance of these companies not only enhances their market valuations but may also lead to upward revisions in earnings expectations for other tech firms, creating a virtuous cycle that could further drive the recovery of the entire industry.
- Future Outlook: As the global economy gradually recovers, the success stories of Apple, Amazon, and TSMC may inspire other companies to adopt similar growth strategies, fostering innovation and investment that drive long-term growth.
See More
Three High-Yield Stocks for Monthly Dividends
- AbbVie's Strong Financials: AbbVie, with a market cap of approximately $370 billion, generated over $61 billion in revenue last year and $20 billion in operating income, demonstrating its ability to grow despite patent expirations, while its 3.3% dividend yield significantly exceeds the S&P 500 average of 1.1%.
- Medtronic's Stability: Medtronic, valued at $101 billion, reported a 9% revenue increase in its latest quarter, with free cash flow of $5.4 billion easily covering its $3.6 billion annual dividend payout, resulting in a 3.6% yield, making it an ideal choice for income-focused investors.
- Enbridge's Consistent Growth: Enbridge, with a market cap of $119 billion, has raised its dividend for 31 consecutive years, with a recent 3% increase, yielding 5.2%, the highest among the listed stocks, and despite a payout ratio over 100%, its distributable cash flow indicates strong financial health.
- Diversified Investment Strategy: By investing in AbbVie, Medtronic, and Enbridge, investors can achieve monthly cash flow, leveraging the different dividend payment schedules of these companies to enhance the stability of their investment portfolio.
See More
Dividend Stocks Comparison: Johnson & Johnson vs. AbbVie
- Diversification Advantage: Johnson & Johnson's diversified operations in pharmaceuticals and medical devices allow it to maintain stability in a competitive market, with revenue growth despite losing Stelara's patent, and it is projected to reach $100 billion in revenue by 2026, becoming only the second biopharma to achieve this milestone in history.
- Core Growth Drivers for AbbVie: AbbVie's leadership in immunology led to $15 billion in revenue in Q1, a 12.4% year-over-year increase, with Skyrizi and Rinvoq contributing $6.6 billion, showcasing strong market performance, though it faces competitive risks.
- Dividend Growth History: Johnson & Johnson has raised its dividends for 64 consecutive years compared to AbbVie's 54 years, indicating stronger financial stability and long-term investment appeal, particularly in the current market environment, with its AAA credit rating further enhancing its attractiveness as a low-risk investment.
- Market Risks and Opportunities: While Johnson & Johnson faces litigation risks related to its talc products, its diversified portfolio enables it to navigate challenges like drug pricing negotiations, whereas AbbVie shows potential in new product launches, especially with its weight-loss treatment performing well in clinical trials.
See More
Analysis of IVV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The IVV ETF's 52-week low is $558.69 per share, with a high of $734.02, and the latest trade at $733.89 indicates stability near its peak, potentially attracting investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- Unit Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding highlights notable inflows (new units created) or outflows (old units destroyed), directly affecting the ETF's underlying holdings and its market performance.
See More
High Dividend Stocks Investors Should Focus On
- AbbVie Dividend Stability: AbbVie declared a quarterly cash dividend of $1.73 per share, and despite losing patent protection for Humira, the company has successfully achieved growth through strategic acquisitions and R&D investments, indicating a strong potential for continued dividends in the future.
- Significant Dividend Growth: Since its spin-off in 2013, AbbVie has increased its dividend by over 332%, with a 33% growth in the past five years, and a current dividend yield of 3.27%, which, although below historical averages, still reflects the company's robust profitability.
- Realty Income's Monthly Dividends: Realty Income, known as
See More
AbbVie and Realty Income's Stable Dividend Prospects
- AbbVie Dividend Growth: AbbVie's board declared a quarterly cash dividend of $1.73 per share, payable on May 15, 2026, demonstrating the company's ability to increase dividends for 54 consecutive years, even amidst patent expiration challenges, while maintaining robust business growth.
- Dividend Yield Performance: AbbVie's forward dividend yield stands above 3.3%, although below its historical average, yet its solid stock price appreciation and 33% dividend growth over the past five years indicate effective inflation management.
- Realty Income Stability: Realty Income has paid dividends for 670 consecutive quarters since going public in 1994, with a forward dividend yield exceeding 5%, showcasing its ability to generate steady cash flow and maintain a high occupancy rate of 98.9% even during economic fluctuations.
- Market Growth Potential: Realty Income's total addressable market is estimated at $13 trillion, with $8.5 trillion in Europe, indicating significant growth potential in a highly fragmented market, which suggests the company can continue to provide substantial monthly dividends to investors.
See More
Apple, Amazon, and TSMC Deliver Earnings Triple Plays
- Earnings Highlights: Apple, Amazon, and TSMC have all achieved a 'triple play' this quarter, delivering growth in earnings, revenue, and guidance, which underscores strong market demand and business resilience, further solidifying their leadership positions in their respective industries.
- Market Reaction: Investors reacted positively to the earnings reports from these three companies, driving stock prices higher, which reflects a renewed confidence in tech stocks and may attract more capital inflows into the technology sector.
- Industry Impact: The robust performance of these companies not only enhances their market valuations but may also lead to upward revisions in earnings expectations for other tech firms, creating a virtuous cycle that could further drive the recovery of the entire industry.
- Future Outlook: As the global economy gradually recovers, the success stories of Apple, Amazon, and TSMC may inspire other companies to adopt similar growth strategies, fostering innovation and investment that drive long-term growth.
See More
Three High-Yield Stocks for Monthly Dividends
- AbbVie's Strong Financials: AbbVie, with a market cap of approximately $370 billion, generated over $61 billion in revenue last year and $20 billion in operating income, demonstrating its ability to grow despite patent expirations, while its 3.3% dividend yield significantly exceeds the S&P 500 average of 1.1%.
- Medtronic's Stability: Medtronic, valued at $101 billion, reported a 9% revenue increase in its latest quarter, with free cash flow of $5.4 billion easily covering its $3.6 billion annual dividend payout, resulting in a 3.6% yield, making it an ideal choice for income-focused investors.
- Enbridge's Consistent Growth: Enbridge, with a market cap of $119 billion, has raised its dividend for 31 consecutive years, with a recent 3% increase, yielding 5.2%, the highest among the listed stocks, and despite a payout ratio over 100%, its distributable cash flow indicates strong financial health.
- Diversified Investment Strategy: By investing in AbbVie, Medtronic, and Enbridge, investors can achieve monthly cash flow, leveraging the different dividend payment schedules of these companies to enhance the stability of their investment portfolio.
See More
